Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2010

View Archived Issues

FDA approves folate-containing oral contraceptive Safyral

UCB claims new PI3K inhibitors

ClanoTech divulges new inhibitors of VEGFR-2 and VEGFR-3

Panobinostat/capecitabine/lapatinib combination is safe in HER2+ breast cancer

Clinical and preclinical data presented on GDC-0941/T-DM1 in HER2+ breast cancer

NS-018 preferentially targets V617F-mutant JAK2

MRx-102 shows promise in models of AML

Enrollment complete in phase IIb COMPONENT trial of vidofludimus in RA

EMA's CHMP recommends approval of Esbriet for IPF

Janssen submits European MAA for telaprevir in chronic hepatitis C

FDA grants fast track status for elacytarabine in AML

Lpath enters into an option license agreement with Pfizer for iSONEP

EMA provides update on safety review for somatropin-containing medicines

Bristol-Myers Squibb and Oncolys sign licensing agreement for festinavir

Manhattan Pharma reports preliminary phase I/II data on AST-915

Scientists identify new susceptibility loci for Hodgkin's lymphoma

GSK and Impax collaborate on late-stage Parkinson's disease therapeutic

New selective JAK1 inhibitors disclosed by Incyte

Idera Pharma reports phase I data on IMO-2125 in hepatitis C

Willfact to be launched in additional European countries

Bayer and Regeneron report topline phase III data on VEGF Trap-Eye

Gilead Sciences acquires Arresto Biosciences

New inhibitors CK II and/or pim-1 discovered at Cylene Pharma

New inhibitors of Aurora kinase A and B presented

Tasigna approved in Japan for newly diagnosed Ph+ CML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...